

PROPOSED AMENDMENTS TO SENATE BILL NO. 2384

Page 1, line 2, after "to" insert "reclassification of medical products using messenger ribonucleic acid technology and"

Page 1, line 3, remove "in the state"

Page 1, line 3, replace "and" with "to provide for a legislative management study;"

Page 1, line 3, after "penalty" insert "; to provide an expiration date; and to declare an emergency"

Page 1, line 7, replace "**Prohibited**" with "**Reclassification - Prohibition**"

Page 1, line 8, after "not" insert "market, advertise,"

Page 1, line 8, after "provide" insert an underscored comma

Page 1, line 9, remove "vaccine developed using"

Page 1, line 9, replace "technology for use in" with "genetic modification agent to"

Page 1, line 10, after "individual" insert ", livestock."

Page 1, line 10, replace "in this state" with "unless a physician or veterinarian directly supervises the procedure and the physician or veterinarian is jointly liable with the corporation that manufactured the vaccine or product for any injury or death caused by the procedure, vaccine, or product"

Page 1, after line 11, insert:

SECTION 2. LEGISLATIVE MANAGEMENT STUDY - VACCINES. During the 2023-24 interim, the legislative management shall consider studying the long-term health effects on human beings of vaccines for respiratory syncytial virus and vaccines developed using messenger ribonucleic acid technology. The study must include input from the department of health and human services, an examination of the potential health risks of the vaccines, and an analysis of the cost of treatment and diagnostics for individuals who suffer any physical injury due to receiving a vaccine for respiratory syncytial virus or a vaccine developed using messenger ribonucleic acid technology. The legislative management shall report its findings and recommendations, together with any legislation necessary to implement the recommendations, to the sixty-ninth legislative assembly.

SECTION 3. EXPIRATION DATE. Section 1 of this Act is effective for two years after its effective date, and after that date is ineffective.

SECTION 4. EMERGENCY. Section 1 of this Act is declared to be an emergency measure."

Re-number accordingly

Introduced by

Senators Magrum, Clemens

Representatives Dyk, Hoverson

1 A BILL for an Act to create and enact a new section to chapter 12.1-31 of the North Dakota
2 Century Code, relating to reclassification of medical products using messenger ribonucleic acid
3 technology and prohibiting the use of vaccines developed using messenger ribonucleic acid
4 technology ~~in the state~~; and to provide for a legislative management study; to provide a penalty;
5 to provide an expiration date; and to declare an emergency.

6 **BE IT ENACTED BY THE LEGISLATIVE ASSEMBLY OF NORTH DAKOTA:**

7 **SECTION 1.** A new section to chapter 12.1-31 of the North Dakota Century Code is created
8 and enacted as follows:

9 **MRNA technology - ~~Prohibited~~ Reclassification - Prohibition - Penalty.**

- 10 1. Notwithstanding any other provision of law, a person may not market, advertise,
11 provide, or administer a vaccine developed using messenger ribonucleic acid
12 technology for use in genetic modification agent to an individual, livestock, or any other
13 mammal in this state unless a physician or veterinarian directly supervises the
14 procedure and the physician or veterinarian is jointly liable with the corporation that
15 manufactured the vaccine or product for any injury or death caused by the procedure,
16 vaccine, or product.
- 17 2. A person that violates this section is guilty of a class A misdemeanor.

18 **SECTION 2. LEGISLATIVE MANAGEMENT STUDY - VACCINES.** During the 2023-24
19 interim, the legislative management shall consider studying the long-term health effects on
20 human beings of vaccines for respiratory syncytial virus and vaccines developed using
21 messenger ribonucleic acid technology. The study must include input from the department of
22 health and human services, an examination of the potential health risks of the vaccines, and an
23 analysis of the cost of treatment and diagnostics for individuals who suffer any physical injury
24 due to receiving a vaccine for respiratory syncytial virus or a vaccine developed using